Short term effect of intranasal administration of hexarelin--a synthetic growth hormone-releasing peptide. Preliminary communication.
Twice or three times daily intranasal administration of the hexapeptide hexarelin for 7 days to children with short stature and normal growth hormone (GH) secretion evoked a significant rise in serum levels of insulin-like growth factor-1 (IGF-1) and alkaline phosphatase. There was also a significant, within normal limits, rise of thyroid stimulating hormone (TSH) without evidence of thyroxine suppression.
Frenkel
J
J
Endocrinology and Diabetes Research Unit, Children's Medical Center of Israel, Petah Tikva.
Silbergeld
A
A
Deghenghi
R
R
Laron
Z
Z
D000281:Administration, Intranasal; D000469:Alkaline Phosphatase / Q000097:blood; D000595:Amino Acid Sequence; D002648:Child; D002675:Child, Preschool; D005260:Female; D006128:Growth / Q000502:physiology; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013006:Growth Hormone / Q000097:blood; D006133:Growth Substances / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D013972:Thyrotropin / Q000097:blood; D013997:Time Factors
D006133:Growth Substances; D009842:Oligopeptides; C086184:hexarelin; D007334:Insulin-Like Growth Factor I; D013972:Thyrotropin; D013006:Growth Hormone; D000469:Alkaline Phosphatase